Our seasoned team has collective experience spanning multiple disciplines including corporate finance, investment research, fund management, consulting, journalism, CFO, in-house communications, business development and accounting.
We use our extensive industry experience to provide clients with unparalleled advice across a broad range of situations from day-to-day PR and IR to crisis management. The breadth and depth of our understanding allow us to provide creative and customised solutions for individual client needs. We have dedicated offices in London and New York and are supported by a global network of offices owned by our parent company Huntsworth plc. We also have preferred access to the expertise of our sister companies at Huntsworth Health with an extensive network of scientific writers, PhDs and physicians.
We provide results-orientated communications strategies at board level to meet your corporate objectives whether they are financing or partnering related. Our team has a unique insight into both areas acquired through direct experience as investors as well as business development for global pharma.
We devise effective communications campaigns to ensure your corporate messages reach their specific target audiences. Together we will work on your positioning to ensure your value driving messages are consistently reinforced in your communications collateral including your website, press releases, presentations, social media and other marketed materials. We are experts in drafting press releases and coordinating newsflow to achieve maximum impact in the specialist trade and business press. Working in partnership with many of the leading industry conference organisers, we are able to maximise visibility and thought leadership by placing our clients on speaker platforms at major partnering and investor events.
While the media landscape is changing dramatically, identifying and getting your key messages to your target audience is as important as ever given the increasingly competitive environment
As a specialist life science and healthcare focused team, we have established excellent relationships and built a reputation with key media that cover sector news and can access senior editors at the leading industry trade publications read by investors, pharma and dealmakers in Europe and US. Getting the most influential journalist’s buy-in validates your corporate and equity story and provides a strong third-party endorsement for you to showcase in your partnering or fundraising discussions.
We are experts in providing strategic counsel and implementation of financial calendar events to our listed clients in multiple markets.
We focus on building the equity story for our clients and communicating the key value drivers through regulated and strategic newsflow, financial reporting and corporate collateral, including annual reports. Through our integrated investor relations offering, we can provide both greater insight into the milestones that drive value in the eyes of investors and decisive issues management. Our excellent relationships with the key business press, newswires, and analysts support the accurate dissemination of your messages to the market. Our goal is to ensure that your equity story is clearly understood, through professional management that results in an appropriate valuation.
CDR's clients benefit from a deep understanding of the key attributes of a successful healthcare investment. We have successful track records in both equities investing across all markets and subsectors of global life sciences and healthcare, as well as execution of healthcare financings as bankers and sell side analysts through various market cycles. Our tenet is to foster long-term relationships between managements, boards and investors to build a broad base of supportive investors who ascribe an appropriate valuation to our clients’ equity.
- IR strategy development and execution
- Messaging and investor presentation
- Institutional investor and sell side analyst targeting and outreach
- Non-deal roadshows and feedback reports
- Market intelligence
- Event planning and execution
- IR website management
- KOL advisory
- Financial modeling and valuation
- Business development/strategic partnership
- Investor day and annual general meeting
Management teams considering the public equity markets benefit from investor relations and communication campaigns that begin well in advance of the IPO and continue seamlessly beyond listing day.
CDR’s emphasis on consistent and durable messaging of the equity story and investment case positively shapes perceptions among multiple external constituencies whilst setting appropriate expectations. This approach ensures the company as an issuer and management team is well-positioned among prospective investment banks, research analysts and institutional investors not only for a successful IPO but also in its evolution as a new public company or already public company listing on a new exchange. Unbiased advice and forging partnerships with advisors who are best fit to execute on behalf of your firm is of paramount importance, and we work closely with clients to successfully navigate the IPO or public listing processes. Our offering includes: Exchange and banker selection, Investor presentation and Q&A, Registration filings, Accompaniment on roadshows, Advice on rational deal pricing and allocation.
We work with our clients to effectively communicate their positioning via their branding and corporate identity.
We keep it fresh by working with a number of trusted design agencies to produce corporate branding for many clients around Europe, from a simple logo design, to extensive concept rebranding, website redesign, corporate and digital presentations and social media. Our offering includes: Management Team workshops and consultation meetings, Inspiration boards, Photographic direction, Art direction, Concept logo designs, Brand guidelines, Website design.
Please get in touch to discuss how we can help support your life sciences efforts.
The Life Sciences Team
Citigate Dewe Rogerson
3 London Wall Buildings
London EC2M 5SY
lifesciences[at]citigatedewerogerson.com // +44 (0) 20 7638 9571
CDR Life Sciences Team supports Acacia Pharma’s €190 million Initial Global Offering
The CDR Life Sciences team supported Acacia Pharma on its successful €190 million Initial Global Offering (IGO) and listing on Euronext Brussels in March 2018. In raising EUR 40 million, Acacia Pharma's
Future of Healthcare Investor Forum
The Citigate Dewe Rogerson Life Sciences team recently co-sponsored the Future of Healthcare Investor Forum alongside J.P. Morgan and Numis and industry partners BIA and OneNucleus.
Back to basics: content, content and… #relevance
We all know that content is king when devising a communications strategy, especially for a traditional media programme. So why is it any different for social media, or at least on the face of it?